Nearly one year after the launch of a drug that increases women's sexual desire, this company's efforts to market it have faltered.
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMAG Pharmaceuticals, Inc. (AMAG) today provided an update regarding the potential impact of COVID-19 on the company. AMAG is committed to the health and safety of its employees, patients, healthcare providers, business partners and communities and is following the guidance from the Center for Disease Control (CDC) and Prevention and local public health authorities, including implementing a work from home policy for all employees. At this time, the company’s supply chain has not been materially affected by COVID-19 and the company continues to closely monitor suppliers and supply levels.
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
Feraheme® (ferumoxytol injection) posts strong first quarter results Company implements a workforce reduction of approximately 30 percent or 140 positions, as part of a planned.
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
At this time I would like to welcome everyone to the AMAG Pharmaceuticals First Quarter 2020 Earnings Call. Good morning and welcome to the AMAG Pharmaceuticals conference call to discuss our first quarter 2020 financial results. Please be reminded that remarks made during this call may include forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
WALTHAM, Mass., April 27, 2020 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its first quarter 2020 financial results will be released on Monday, May 11,.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that management will participate at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:00 p.m. Eastern Time. A live audio webcast of the virtual event will be accessible through the Investors section of the company’s website at www.amagpharma.com. AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs.
Q4 2019 AMAG Pharmaceuticals Inc Earnings Call
AMAG Pharmaceuticals, Inc. (AMAG) today announced that its Board of Directors has appointed Scott Myers as AMAG’s President and Chief Executive Officer, and member of the Board, effective immediately. Mr. Myers succeeds William Heiden, who is stepping down from such roles in light of Mr. Myers’ appointment. “Scott is a seasoned leader with exceptional experience, skill set and passion, and it became evident to the Board through its rigorous search that Scott is the ideal candidate to lead AMAG forward,” said Gino Santini, Chairman of AMAG’s Board.
If you own shares in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) then it's worth thinking about how it contributes to the...
AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) remained unaffected at $9.23 after the company reported Q1 results.Quarterly Results Earnings per share were up 20.00% over the past year to ($0.72), which might not be comparable to the estimate of ($0.03).Revenue of $68,661,000 lower by 9.42% year over year, which beat the estimate of $64,820,000.Guidance Earnings guidance hasn't been issued by the company for now.AMAG Pharmaceuticals hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 11, 2020View more earnings on AMAGTime: 08:00 PM ETWebcast URL: https://edge.media-server.com/mmc/p/ok5yt4pwRecent Stock Performance Company's 52-week high was at $13.53Company's 52-week low was at $4.41Price action over last quarter: Up 19.25%Company Profile AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.See more from Benzinga * Recap: Recro Pharma Q1 Earnings * Recap: GNC Holdings Q1 Earnings * Pieris Pharmaceuticals: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has completed the sale of its rights to Intrarosa® (prasterone) to Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group in 2018 that specializes in women’s health and menopause-related conditions, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million. “As mentioned in our first quarter earnings release, the sale of Intrarosa is an important step in our strategic evolution,” said Scott Myers AMAG’s president and chief executive officer.